Literature DB >> 406939

Sympathetic adrenergic blockade effects upon operantly conditioned blood pressure elevations in baboons.

D S Goldstein, A H Harris, J V Brady.   

Abstract

Sympathetic adrenergic nervous activity during operantly conditioned hypertension was evaluated by assessing the effects of specific alpha-(phentolamine or phenoxybenzamine) and beta- (propranolol) adrenergic blockers in baboons reinforced for increasing diastolic pressure in daily, 12-h sessions. In the first 10 min of control (no blockade) sessions, mean heart rate increased 24 bpm (21%) above the value for the 10 min immediately prior to the beginning of the sessions; systolic pressure increased 27 mm Hg (22%) and diastolic pressure increased 24 mm Hg (31%). Beta-blockade eliminated the tachycardia but did not attenuate the increased blood pressure. Alpha-blockade did not attenuate the increased blood pressure significantly either. Combined alpha- and beta-blockade did significantly attenuate the increase in diastolic pressure, but consistent, significant increases in systolic pressure (17 mm Hg, 17%) and diastolic pressure (16 mm Hg, 26%) still occurred. The results support the participation of the sympathetic adrenergic nervous system in producing operantly conditioned blood pressure changes, but the results are also consistent with the additional participation of nonadrenergic factors in operantly conditioned hypertension.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 406939     DOI: 10.1007/bf01001722

Source DB:  PubMed          Journal:  Biofeedback Self Regul        ISSN: 0363-3586


  13 in total

1.  A TECHNIQUE FOR CONTINUOUS MEASUREMENT OF ARTERIAL BLOOD PRESSURE IN UNANESTHETIZED MONKEYS.

Authors:  D WERDEGAR; D G JOHNSON; J W MASON
Journal:  J Appl Physiol       Date:  1964-05       Impact factor: 3.531

2.  Mechanisms of inhibition of heart rate by phenylephrine.

Authors:  S VARMA; S D JOHNSEN; D E SHERMAN; W B YOUMANS
Journal:  Circ Res       Date:  1960-11       Impact factor: 17.367

3.  A restraint system for chronic study of the baboon.

Authors:  J D Findley; W W Robinson; W Gilliam
Journal:  J Exp Anal Behav       Date:  1971-01       Impact factor: 2.468

4.  A study of the adrenotropic receptors.

Authors:  R P AHLQUIST
Journal:  Am J Physiol       Date:  1948-06

5.  Selective autonomic blockade of conditioned and unconditioned cardiovascular changes in rhesus monkeys (Macaca mulatta).

Authors:  K J Klose; J S Augenstein; N Schneiderman; K Manas; B Abrams; L J Bloom
Journal:  J Comp Physiol Psychol       Date:  1975-09

Review 6.  Parasympathetic control of the heart.

Authors:  C B Higgins; S F Vatner; E Braunwald
Journal:  Pharmacol Rev       Date:  1973-03       Impact factor: 25.468

7.  Hemodynamic effects of angiotensin in normal and environmentally stressed monkeys.

Authors:  R P Forsyth; B I Hoffbrand; K L Melmon
Journal:  Circulation       Date:  1971-07       Impact factor: 29.690

8.  Behavioral activities and cardiovascular functions: effects of hexamethonium on cardiovascular changes during strong sustained static work in rhesus monkeys.

Authors:  P B Dews; J A Herd
Journal:  J Pharmacol Exp Ther       Date:  1974-04       Impact factor: 4.030

9.  Effects of propranolol, phentolamine and methyl atropine on cardiovascular function in the squirrel monkey during behavioral experiments.

Authors:  R T Kelleher; W H Morse; J A Herd
Journal:  J Pharmacol Exp Ther       Date:  1972-08       Impact factor: 4.030

10.  Instrumental conditioning of large-magnitude, daily, 12-hour blood pressure elevations in the baboon.

Authors:  A H Harris; W J Gilliam; J D Findley; J V Brady
Journal:  Science       Date:  1973-10-12       Impact factor: 47.728

View more
  2 in total

1.  Instrumental cardiovascular conditioning: a review.

Authors:  D S Goldstein
Journal:  Pavlov J Biol Sci       Date:  1979 Apr-Jun

2.  Performance characteristics of conditioned blood pressure elevations in the baboon.

Authors:  A H Harris; J S Turkkan
Journal:  Biofeedback Self Regul       Date:  1981-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.